Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR2150 and Efavirenz Interaction Study
NCT05141422Phase 1Unknown
- Sponsor
- Hengrui
- Start
- Dec 2021
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SHR2150 in human immunodeficiency virus infection (HIV), sponsored by Hengrui. Primary endpoints: Time to Maximum Plasma Concentration, Maximum Plasma Concentration and 3 more. Status: unknown.
02
Drugs
SHR2150
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT05141422.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05141422.